PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer  by Dupuy, Fanny et al.
ArticlePDK1-Dependent Metabolic Reprogramming
Dictates Metastatic Potential in Breast CancerGraphical AbstractHighlightsd Breast cancer cells display unique metabolic signatures
depending on metastatic site
d HIF-1a/PDK1 promotes glycolytic metabolism in liver-
metastatic breast cancer cells
d PDK1 is required for efficient formation of liver metastases
d PDK1 expression is elevated in human liver metastasesDupuy et al., 2015, Cell Metabolism 22, 577–589
October 6, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.cmet.2015.08.007Authors
Fanny Dupuy, Se´bastien Tabarie`s,
SylviaAndrzejewski, ..., Julie St.-Pierre,
Russell G. Jones, Peter M. Siegel
Correspondence
russell.jones@mcgill.ca (R.G.J.),
peter.siegel@mcgill.ca (P.M.S.)
In Brief
Dupuy et al. reveal that primary breast
cancer cells display extensive metabolic
heterogeneity and differentially engage
glycolysis or OXPHOS depending on their
site of metastasis (liver, lung, or bone).
Liver metastases rely on a HIF-1a/PDK1-
dependent axis for their intrinsic
metabolic reprogramming, which enables
their efficient colonization and growth in
the liver.
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Metabolic reprogramming is a hallmark of cellular
transformation, yet little is known about metabolic
changes that accompany tumor metastasis. Here
we show that primary breast cancer cells display
extensive metabolic heterogeneity and engage
distinct metabolic programs depending on their site
of metastasis. Liver-metastatic breast cancer cells
exhibit a unique metabolic program compared to
bone- or lung-metastatic cells, characterized by
increased conversion of glucose-derived pyruvate
into lactate and a concomitant reduction in mito-
chondrial metabolism. Liver-metastatic cells dis-
played increased HIF-1a activity and expression of
the HIF-1a target Pyruvate dehydrogenase kinase-1
(PDK1). Silencing HIF-1a reversed the glycolytic
phenotype of liver-metastatic cells, while PDK1 was
specifically required for metabolic adaptation to
nutrient limitation and hypoxia. Finally, we demon-
strate that PDK1 is required for efficient liver metas-
tasis, and its expression is elevated in liver metasta-
ses from breast cancer patients. Our data implicate
PDK1 as a key regulator of metabolism and metasta-
tic potential in breast cancer.
INTRODUCTION
The emergence of metastatic breast cancer is the most deadly
aspect of the disease, as it is largely incurable once tumor cells
have spread from the primary site. Breast cancer metastasis is
a complex multistep process, in which each step represents a
significant barrier tometastatic progression, themost formidable
being the foreign microenvironment to which disseminated can-Cellcer cells must adapt. How tumor cells overcome these barriers
during metastasis is critical for successful dissemination and
yet remains a poorly understood process.
One of the fundamental hallmarks of cancer is the reprogram-
ming of cellular metabolism to promote tumor cell growth, pro-
liferation, and survival (Hanahan and Weinberg, 2011). One of
the primary metabolic changes associated with cellular trans-
formation is increased aerobic glycolysis, also known as the
‘‘Warburg effect’’ (Vander Heiden et al., 2009; Warburg,
1956); however, recent work has established equally important
roles for mitochondrial metabolism—the TCA cycle and oxida-
tive phosphorylation (OXPHOS)—in tumor progression (Ahn
and Metallo, 2015). Interactions between cancer cells and non-
transformed cells within the tumor microenvironment, such
as cancer-associated fibroblasts, may also create codepen-
dencies that help fuel the metabolic requirements of rapidly
proliferating tumor cells (Chiavarina et al., 2011; Martinez-Out-
schoorn et al., 2014).
While considerable advances have been made in under-
standing how metabolic changes fuel the growth of primary
tumor cells, the influence of metabolic reprogramming on the
metastatic process is poorly understood. In the current study,
we sought to characterize the intrinsic metabolic profiles of
breast cancer cells as they spread to different metastatic sites
commonly observed in human breast cancer (i.e., bone, lung,
and liver). Our results indicate that while aggressively metasta-
tic breast cancer cells displayed elevated glycolysis and
OXPHOS relative to non-metastatic tumor cells, the metabolic
profiles of breast cancer cells differed based on their site of
metastasis. Here we have investigated the role of the Hypox-
ia-inducible factor-1a (HIF-1a), and its downstream target
PDK1, in the regulation of metabolic reprogramming and meta-
static potential in liver-metastatic breast cancer cells. Together,
our data suggest that there is metabolic heterogeneity in
metastatic breast cancer, and that these metabolic programs
may dictate successful colonization and metastatic tumor
growth at distinct sites.Metabolism 22, 577–589, October 6, 2015 ª2015 Elsevier Inc. 577
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Figure 1. Increased Metabolic Activity Accompanies Enhanced Metastatic Potential
(A) Schematic of murine breast cancer cells and their associated metastatic phenotypes.
(B and C) ECAR (B) and OCR (C) are expressed as a fold change relative to 67NR.
(D) Plot representing the ratio of OCR/ECAR for each breast cancer population.
(E) Breast cancer cells were assayed for their maximal respiration measured following addition of FCCP (1.5 mM) (n = 3).
(F–H) Cells were pulsed with U-[13C]-glucose for 30 min, and [13C] incorporation into pyruvate (F), lactate (G), and citrate (H) was determined by GC-MS. Data
represent abundance of the labeled portion of the indicatedmetabolite relative to 67NR for one representative experiment performed in duplicate. (B) ***p < 0.001
(SD); (C) ***p < 0.001 (SD); *p < 0.05 (SD); (E) ***p < 0.001 (SD); *p < 0.05. (SD).RESULTS
Metastatic Breast Cancer Cells Display Increases in
Both Glycolytic and Oxidative Metabolism
To assess metabolic differences in cancer cells exhibiting
different tumorigenic and metastatic phenotypes, we used three
murine breast cancer cell populations: 67NR cells that are non-
metastatic, 66cl4 cells that metastasize to the lungs, and 4T1
cells that spread to various sites, including lymph nodes, bone,
lung, and liver (Aslakson and Miller, 1992) (Figure 1A). We con-
ducted bioenergetic profiling of these cells using the Seahorse
XF-Bioanalyzer platform. Previous reports have shown that
metastatic cancer cells possess higher levels of both glycolytic
and TCA-derived metabolic intermediates relative to non-meta-
static cells (Lu et al., 2010). Consistent with these results,
metastatic 4T1 cells displayed an2-fold increase in their extra-
cellular acidification rate (ECAR; Figure 1B), as well as increased
glucose consumption and lactate production (see Figures S1A
and S1B available online), relative to non-metastatic 67NR cells.
Moreover, both metastatic breast cancer cell populations (66cl4
and 4T1) displayed a higher oxygen consumption rate (OCR)
relative to 67NR cells (Figure 1C). This corresponded to578 Cell Metabolism 22, 577–589, October 6, 2015 ª2015 Elsevier Inincreased OCR/ECAR ratios that were related to the metastatic
potential of the breast cancer cells (Figure 1D), with 4T1 cells ex-
hibiting significant increases in both OCR and ECAR while 66cl4
exhibited increases only in OCR. Metastatic cell populations
(66cl4 and 4T1) also displayed a higher maximal respiration
rate relative to 67NR cells (Figure 1E), suggesting greater oxida-
tive capacity relative to non-metastatic breast cancer cells iso-
lated from the same parental tumor. We further determined
that these metabolic differences were not a direct consequence
of increased proliferation rates, which were similar between all
cell populations (Figure S1C).
We next performed stable isotope tracer analysis (SITA)
using U-[13C]-glucose to assess how metastatic breast cancer
cells utilize glucose. Cells were pulsed with U-[13C]-glucose for
30 min and the abundance of [13C]-derived metabolites
measured by GC-MS (schematic in Figure S1D). We observed
an increase in the total abundance of [13C]-glucose-derived
pyruvate in cells with increasing metastatic potential: 66cl4
and 4T1 cells exhibited 2.5-fold and 6-fold increases in
the total amount of [13C]-glucose-derived pyruvate, respec-
tively, relative to 67NR cells (Figure 1F). The amount of intra-
cellular pyruvate was not dramatically different between cellc.
populations; however, the percentage of the pyruvate pool
labeled from [13C]-glucose was significantly increased in
both 66cl4 and 4T1 cells relative to 67NR cells (Figure S1E),
the majority of which was labeled as the m+3 isotopomer
(Figure S1F).
Pyruvate can be converted into lactate to regenerate NAD,
which is a hallmark of the Warburg effect. Alternatively, it can
be converted to acetyl-CoA and further metabolized in the TCA
cycle. Despite an increase in the glucose-derived pyruvate
pool in the metastatic cells, we did not observe increased
conversion of glucose-derived pyruvate to intracellular lactate
(Figures 1G, S1G, and S1H). Rather, total pools and [13C]-
glucose-derived citrate followed the same trends as [13C]-
glucose-derived pyruvate (Figure 1F), which were increased in
metastatic breast cancer cells (Figures 1H and S1I), with the pre-
dominant form being the m+2 isotopomer (Figure S1J).
The increased ECAR measurements observed in 4T1 cells
(Figure 1B) suggest that they should be producing more lactate;
however, levels of intracellular glucose-derived lactate were
similar between all cell lines (Figure 1G). To confirm that 4T1 cells
were indeed directing a larger portion of glucose into lactate,
SITA was performed using conditioned media harvested from
67NR, 66cl4, and 4T1 cells. In agreement with our previous find-
ings, 4T1 cells exhibit elevated levels of total pool and [13C]-
labeled extracellular lactate compared to 67NR and 66cl4 cells
(Figure S1K), with the majority of the label found as the m+3 iso-
topomer (Figure S1L). Thus, unlike the conventional Warburg
phenotype of primary tumor cells, highly metastatic breast can-
cer cells engage both glycolytic and oxidative metabolism. More
importantly, these results reveal that metastatic breast cancer
cells with varying degrees of metastatic fitness can differentially
engage one (66cl4; OXPHOS) or multiple (4T1; glycolytic and
OXPHOS) metabolic strategies.
Organ-SelectiveMetastatic Breast Cancer Cells Display
Distinct Metabolic Programs
We next assessed whether metastatic breast cancer cells retain
their metabolic phenotype following colonization of distinct
metastatic sites. We previously subjected parental 4T1 cells to
an in vivo selection protocol to derive subpopulations with
increased selectivity for colonization and growth in specific or-
gans. We established multiple cell populations per site—the
bone (592 and 593), the lung (533 and 537), and the liver (2776
and 2792)—and confirmed that, although they retain the poten-
tial to metastasize to all sites, they display an increased ability to
colonize the site fromwhich they were isolated (Rose et al., 2007,
2010; Tabarie`s et al., 2011) (Figure 2A). Using gene expression
profiling data generated from parental 4T1 cells and each of
these site-selective metastatic cell populations, we assembled
a composite metabolic gene expression signature based on
KEGG designations (Table S1). Using this composite metabolic
signature, we observed a distinct gene expression pattern in
liver-metastatic 4T1 subpopulations (2776 and 2792) relative to
parental 4T1, bone-metastatic (592 and 593), and lung-metasta-
tic (533 and 537) cells (Figure 2B). Liver-metastatic 4T1 cells
displayed enrichment for genes encoding components of the
glycolytic pathway (Figure 2C), including Aldolase, Lactate
dehydrogenase, Phosphofructokinase, Glucose phosphate
isomerase, and Enolase (Table S2), while displaying reducedCellexpression of genes involved in the TCA cycle and OXPHOS
(Figure 2D; Table S3).
We next conducted SITA using U-[13C]-glucose on the organ-
selective metastatic cell populations (bone, lung, and liver),
and found differences in glucose utilization depending on the
metastatic site. For these experiments, we pulsed cells with
U-[13C]-glucose for 30 min and displayed the averaged data of
two independent explant populations for each metastatic site.
Overall pyruvate abundance was elevated in all organ-selective
metastatic populations relative to parental 4T1 cells (Figure S2A),
with 13C incorporation corresponding to the m+3 isotopomer
(Figure S2B). Taking into account both the metabolite pool size
and 13C enrichment in each pool, we found that bone-metastatic
cells displayed an increase in the total amount of U-[13C]-
glucose-labeled pyruvate, while the production of U-[13C]-
glucose-derived pyruvate in lung and liver-metastatic cells was
similar to parental 4T1 cells (Figure 2E). Overall, lactate pools
were elevated in all metastatic explants compared to parental
4T1 cells (Figure S2C); however, liver-metastatic breast cancer
cells displayed a specific increase in labeling of lactate from
U-[13C]-glucose (Figures 2F, S2C, and S2D). Bone- and lung-
metastatic cell populations displayed an increase in both
total citrate abundance and levels of glucose-derived citrate
compared to parental 4T1 cells (Figures 2G and S2E).
Conversely, liver-metastatic cells displayed a slight decrease
in the levels of glucose-derived citrate relative to parental 4T1
cells (Figures 2G), corresponding to an increase in the abun-
dance of the m+0 isotopomer in liver-metastatic cells, along
with a decrease in the m+2 isotopomer (Figures S2E and S2F).
To confirm these results, we performed SITA experiments us-
ing a shorter labeling period (15 min pulse with U-[13C]-glucose)
on the individual liver-metastatic cell lines (denoted 2776 and
2792). We observed that, while the total pyruvate pool did not
significantly change (Figure S2G), the fraction of pyruvate
derived fromU-[13C]-glucosewas increased in the liver-metasta-
tic cells compared to parental 4T1 cells (Figure S2G), resulting in
an increased abundance of labeled lactate (Figure 2H). Similarly,
we observed an increase in the overall lactate pool (Figure S2H)
as well as the fraction derived from U-[13C]-glucose (72% and
79% relative to 43%). This analysis revealed elevated levels of
glucose-derived lactate in liver-metastatic cells compared to
parental 4T1 cells (Figures 2I and S2H). In contrast, we observed
a significant reduction in both the fraction (Figures S2I–S2L) and
abundance of U-[13C]-glucose-derived citrate (Figure 2J) in 2776
and 2792 liver-metastatic cells, while the total pool was only
slightly decreased (Figure S2I). Isotopomer labeling patterns
for pyruvate, lactate, and citrate in liver-aggressive metastatic
cells were in agreement with our earlier observations (Figures
S2J–S2L). Together, these data indicate that breast cancer cells
display distinct metabolic signatures depending on the metasta-
tic site.
Liver-Metastatic Breast Cancer Cells Display Reduced
Glutamine Metabolism and OXPHOS
Another aspect of aggressive cancer cells that display the War-
burg effect is increased glutamine metabolism (DeBerardinis
et al., 2007). Glutamine is a key anaplerotic substrate for the
TCA cycle through its conversion to a-ketoglutarate (a-KG)
(Figure S3A) (Hensley et al., 2013). To assess differences inMetabolism 22, 577–589, October 6, 2015 ª2015 Elsevier Inc. 579
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Figure 2. Organ-Selective Metastatic Breast Cancer Cells Display Differential Glucose Utilization
(A) Schematic depicting the origin of in vivo selected metastatic breast cancer cell populations.
(B) The expression level of 680 genes, representingmajor cellularmetabolic pathways (Table S1), was compared between the parental 4T1 and the various organ-
selective metastatic cell populations.
(C and D) (C) Genes in the glycolysis (43 genes) and (D) OXPHOS pathways (136 genes) are shown in detail. The identity of genes corresponding to areas A and B
of the heatmaps are listed in Tables S2 and S3, respectively.
(E–J) SITA measuring the conversion of U-[13C]-glucose into pyruvate (E and H), lactate (F and I), and citrate (G and J). The data represent abundance of the
labeled portion of the indicatedmetabolite relative to 4T1 cells. (E–G) Organ-selectivemetastatic cell populations and 4T1 parental cells were pulsedwith U-[13C]-
glucose for 30min and the presented data correspond to the average of two independent cell populations each performed in duplicate. (H–J) Liver-metastatic cell
populations and 4T1 parental cells were pulsed with U-[13C]-glucose for 15 min. (E) *p < 0.05 (SD); (G) *p < 0.05 (SD).glutamine utilization by organ-selectivemetastatic breast cancer
cells, two independent explant populations from eachmetastatic
site were cultured with U-[13C]-glutamine for 30 min and TCA cy-
cle metabolites analyzed using GC-MS. Bone- and lung-meta-
static populations displayed increasedU-[13C]-glutamine uptake
and total glutamine pools relative to 4T1 parental cells (Figures
3A and S3B), as well as increased abundance of U-[13C]-gluta-
mine-derived TCA cycle intermediates including succinate (Fig-
ures 3B and S3C) and citrate (Figures 3C and S3D; left panel). In
contrast, glutamine uptake in liver-metastatic cells was similar
to parental 4T1 cells (Figures 3A and S3B), and the levels of
total and glutamine-derived TCA cycle metabolites were either
reduced (succinate, Figures 3B and S3C) or unchanged (citrate,
Figures 3C and S3D; left panel) in liver-metastatic subpopula-580 Cell Metabolism 22, 577–589, October 6, 2015 ª2015 Elsevier Intions compared to parental 4T1 cells. However, the overall frac-
tions of the total pool for each metabolite labeled from glutamine
were similar in all cell populations (Figure S3). Analysis of the in-
dividual liver-metastatic populations (2776 and 2792) revealed
additional differences compared to the parental 4T1 cells with
a further shift away from oxidative glutamine metabolism. We
observed a 60% reduction in glutamine pools in the 2776 and
2792 liver-metastatic cells compared to parental 4T1 cells (Fig-
ures 3D and S3E), which translated into a decrease in total pools
and [13C]-glutamine-derived abundance of the TCA cycle inter-
mediates succinate, citrate, fumarate, malate and aspartate (Fig-
ures 3E–3I and S3F–S3J).
Cancer cells with diminished mitochondrial activity often
engage reductive carboxylation (schematic in Figure S3A) toc.
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B C Figure 3. Liver-Metastatic Breast Cancer
Cells Display Reduced Oxidative Glutamine
Metabolism and Oxidative Phosphorylation
Measurement of glutamine uptake into cells (A and
D) and its conversion into succinate (B and E),
citrate (C and F), fumarate (G), malate (H), and
aspartate (I). Data represent the abundance of the
labeled portion of the indicated metabolite relative
to 4T1 cells.
(A–C) Organ-selective metastatic cell populations
and 4T1 parental cells were pulsed with U-[13C]-
glutamine for 30 min. Data correspond to the
average of two independent cell populations, each
performed in duplicate.
(D–F) The same experiment was repeated in the
liver-metastatic cell populations and 4T1 parental
cells, and each graph represents the data for a
single cell population performed in duplicate.
(J) The graph represents the distribution of the
[13C] label between the m+4 and m+5 isoforms of
citrate.
(K) Total cellular respiration was assayed for the
liver-metastatic cells lines. The data correspond to
an average of five experiments and are expressed
as a fold change relative to 4T1 cells.
(L) Mitochondrial-specific ROS were analyzed
using MitoSox and are plotted as a fold change
relative to 4T1 cells.
(A) *p < 0.05 (SD); (B) *p < 0.05 (SD); (C) *p < 0.05
(SD); (K) *p < 0.05 (SEM); (L) *p < 0.05 (SEM).generate glutamine-derived acetyl-CoA that contributes to
biosynthetic pathways such as lipid biosynthesis (Metallo
et al., 2012). Liver-metastatic cells exhibited a 40% increase in
reductive carboxylation (as indicated by increased m+5 citrate
in 2776 and 2792 cells) compared to parental 4T1 cells (Fig-
ure 3J), suggesting differences in carbon flow in these cell pop-
ulations. Interestingly, levels of the m+5 citrate isotopomer in
bone- and lung-metastatic cells did not differ from that seen in
parental 4T1 cells (Figure S3D; right panel).
Finally, we assessed the impact of reduced carbon flow into
the TCA cycle on rates of OXPHOS in liver-metastatic cells.
Liver-metastatic breast cancer cells (2776 and 2792) displayed
a 40%–50% reduction in total respiration relative to parental
cells (Figure 3K). One expected consequence of lowermitochon-
drial activity is reduced production of reactive oxygen species
(ROS). Levels of mitochondrial ROS were 30%–40% lower in
liver-metastatic cells compared to parental 4T1 cells (Figure 3L).
Together, these data indicate that oxidative glutamine meta-Cell Metabolism 22, 577–58bolism is reduced in liver-metastatic
breast cancer cells, while glutamine ana-
plerosis is a salient feature of lung- and
bone-metastatic cells.
HIF-1aMediates Metabolic
Reprogramming of Liver-Metastatic
Breast Cancer Cells
HIF-1a is a master transcription factor
that controls metabolic reprogramming
under low-O2 conditions, and it functions
as a key regulator of glycolysis (Keithet al., 2012; Semenza, 2013). We assessed HIF-1a activity in
metastatic breast cancer cells using a reporter system
comprised of HIF responsive elements (HRE) controlling lucif-
erase expression (Yan et al., 2014). HIF-1a transcriptional activ-
ity was elevated under normoxic conditions in liver-metastatic
cell populations and could be further induced under hypoxic
conditions (Figure 4A). Despite no evidence of increased
HIF-1a protein expression (Figure 4B), liver-metastatic cells
(2776 and 2792) displayed modestly elevated expression
of Hif-1a mRNA and a significant increase in expression of
HIF-1a-dependent target genes, including major enzymes of
the glycolytic pathway (Figure 4C).
To assess the contribution of HIF-1a to the observed meta-
bolic program, two independent shRNAs were used to silence
HIF-1a protein expression in 2776 and 2792 liver-metastatic
cell populations (Figure 4D). SITA using U-[13C]-glucose re-
vealed no major changes in the relative abundance of labeled
pyruvate generated from U-[13C]-glucose between parental9, October 6, 2015 ª2015 Elsevier Inc. 581
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Figure 4. HIF-1a Is Hyperactivated in Liver-Metastatic Breast Cancer Cells and Partially Drives Metabolic Reprogramming
(A) HIF-1 transcriptional activity under basal and hypoxic conditions. The data correspond to an average of three experiments performed in duplicate.
(B) Immunoblot analysis of HIF-1a in 4T1 parental cells and the liver-metastatic 4T1 subpopulations. a-Tubulin served as a loading control.
(C) Expression levels of HIF-1a and known HIF target genes were analyzed by RT-qPCR. The data represent an average of two independent experiments,
each performed in duplicate.
(D) Immunoblot analysis to assess efficiency of HIF-1a knockdown. a-Tubulin served as a loading control.
(E–J) SITA using U-[13C]-glucose for 15 min (E–G) or U-[13C]-glutamine for 30min (H–J). The data represent the abundance of the [13C] incorporated into pyruvate
(E), lactate (F), and citrate (G) derived from glucose; or the labeled glutamine within the cells (H) and its incorporation into succinate (I) or citrate (J).
(K) Total cellular respiration was measured in 2776, vector control, and HIF-1a KD cells. The data correspond to an average of three experiments and are
expressed as a fold change relative to 2776 cells.
(L and M) Quantification of the metastatic burden in the liver (L) and the lung (M) following injection with control and HIF-1a KD cells (n = 8 for splenic injections
of 2776-EV and 2776-shHIF-1a; n = 8 for tail vein injections of 2776-EV and n = 9 for 2776-shHIF-1a).
(A) *p < 0.05 (SEM); (C) *p < 0.05 (SD); (F) ***p < 0.001 (SD); (H) ***p < 0.001 (SD); (I) *p < 0.05 (SD); (J) *p < 0.05 (SD); (K) *p < 0.05 (SEM); (L) *p < 0.05 (SEM);
(M) *p < 0.05 (SEM).liver-aggressive cells and those expressing a control vector (EV)
or HIF-1a-specific shRNA (shHIF-1a) (Figure 4E). However,
silencing HIF-1a in liver-aggressive cells effectively reversed
the fate of pyruvate in these cells, as evidenced by an increase
in the abundance of [13C]-glucose-derived citrate (Figure 4F)
and a decrease in [13C]-glucose-derived lactate (Figure 4G).
Silencing HIF-1a promoted increased [13C]-glutamine uptake
by liver-metastatic cells (Figure 4H), as well as an increase of
[13C]-glutamine-derived TCA cycle metabolites including succi-
nate (Figure 4I) and citrate (Figure 4J). Finally, we observed a
significant increase in respiration in liver-metastatic cells ex-
pressing HIF-1a shRNAs compared to control populations
(Figure 4K). These results suggest that HIF-1a is a major driver
of the metabolic phenotype (glycolysis > OXPHOS) in the liver-
metastatic explant populations studied here.582 Cell Metabolism 22, 577–589, October 6, 2015 ª2015 Elsevier InWe next determined the importance of the HIF-1a pathway for
the metastatic potential of these breast cancer cells. Experi-
mental metastasis assays were performed by injecting HIF-1a
knockdown (KD) and empty vector (EV) control cells into either
the spleen or the tail vein, and colonization of the liver (Figure 4L)
and lungs (Figure 4M), respectively, was assessed. Silencing
HIF-1a impaired the capacity of the breast cancer cells tometas-
tasize to both sites, resulting in a 50% reduction of themetastatic
burden in the lungs and liver relative to controls.
PDK1 Mediates Adaption to Metabolic Stress in
Liver-Metastatic Breast Cancer Cells
Pyruvate dehydrogenase kinase-1 (PDK1) is a HIF-1a target that
antagonizes the function of Pyruvate dehydrogenase (PDH), a
key rate-limiting enzyme for pyruvate conversion to acetyl-coAc.
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Figure 5. PDK1 Is Required for Metabolic Adaption of Breast Cancer Cells in Response to Stress
(A) Immunoblot analysis of PDK1 levels in liver-metastatic breast cancer cells compared to 4T1 parental cells.
(B) Immunoblot analysis of HIF-1a and PDK1 in the liver-metastatic breast cancer cells following HIF-1a KD.
(C) Immunoblot analysis showing the efficiency of PDK1 KD in the liver-metastatic 4T1 subpopulations. a-Tubulin served as a loading control (A–C).
(D–G) SITA measuring the conversion of U-[13C]-glucose into pyruvate, lactate, succinate, and citrate in regular growth media (D) or cultured 24 hr either with 1%
O2 (E) or 1 mM glucose (F). Data represent relative abundance of the labeled portion of the indicated metabolite for one representative experiment performed in
duplicate.and entry into the TCA cycle. PDK1-dependent inhibition of PDH
reduces the conversion of pyruvate to acetyl-CoA, leading to
reduced flow of glucose-derived pyruvate into the TCA cycle,
especially under hypoxic conditions (Kim et al., 2006; Papan-
dreou et al., 2006). Consistent with the 4-fold increase in Pdk1
mRNA expression seen in liver-metastatic explants (Figure 4C),Cellwe observed increased PDK1 protein levels in the 2776 and
2792 liver-aggressive populations compared to parental
4T1 cells (Figure 5A). PDK1 expression in these cells was
dependent on HIF-1a, as PDK1 protein levels were reduced in
liver-metastatic cells expressing HIF-1a shRNAs (Figure 5B).
The functional consequences of reduced HIF-1a levels, causingMetabolism 22, 577–589, October 6, 2015 ª2015 Elsevier Inc. 583
diminished PDK1 expression, was revealed by impaired serine
phosphorylation of PDH on residue 203 (Site 3), a PDK1-specific
phosphorylation site (Figure S4A).
It is conceivable that variable levels of PDK1 exist in the
parental 4T1 cell population and are selected for following seed-
ing of the liver. Alternatively, PDK1 expression may be absent
in the parental population and induced following colonization
of the liver and growth of hepatic metastases. PDK1 immunohis-
tochemical staining of primary mammary tumors derived from
parental 4T1 cells revealed variable PDK1 expression in 4T1
tumors (Figure S4B). In addition, we isolated several clonal
populations derived from parental 4T1 cells and assessed
PDK1 protein expression. The expression of PDK1 in 4T1 cell
clones was diverse, with some clones negative for PDK1 and
others exhibiting levels comparable to the 2776 liver-metastatic
population (Figure S4C). These data argue that a pre-existing
population of PDK1-expressing cells is likely selected for during
the formation of liver metastases.
The contribution of PDK1 to the metabolic reprogramming of
liver-metastatic cell populations was next assessed through
shRNA-mediated silencing of PDK1 (Figure 5C). Surprisingly,
under normal culture conditions we observed no differences in
the ECAR, OCR, or total respiration rates of PDK1 shRNA-ex-
pressing liver-metastatic 2776 cells (2776-shPDK1) relative to
parental cells or 2776 cells expressing a control shRNA targeting
luciferase (2776-shLUC) (Figures S4D–S4F). Similarly, unlike
their counterparts expressing HIF-1a shRNAs, liver-metastatic
cells expressing PDK1 shRNAs did not display significant
changes in levels of [13C]-glucose-derived lactate, succinate,
or citrate (Figure 5D). However, PDK1 was required for Ser-203
PDH phosphorylation under both normoxic and hypoxic condi-
tions (Figure S4G), and was required to mediate metabolic
adaptations to low oxygen (1% O2) or low glucose (1 mM).
Liver-metastatic cells expressing PDK1 shRNA displayed a
dramatic reduction in the abundance of [13C]-glucose-derived
pyruvate under hypoxia (Figure 5E). This did not correlate with
changes in intracellular lactate production under hypoxia; rather,
2776-shPDK1 cells displayed a striking increase in levels of
[13C]-glucose-derived succinate and citrate in response to hyp-
oxia (Figure 5E), consistent with increased pyruvate flow into the
TCA cycle. Conversely, low-glucose conditions did not affect the
relative abundance of labeled pyruvate or lactate in liver-meta-
static cells, but specifically promoted the accumulation of
[13C]-glucose-derived succinate and citrate in liver-metastatic
cells expressing PDK1 shRNA (Figure 5F). Thus, PDK1 ex-
pression appeared to alter the flow of 13C-glucose carbon to
the TCA cycle specifically under low-oxygen and low-glucose
conditions.
PDK1 Expression Is Required for Efficient Breast
Cancer Liver Metastasis
We next assessed the impact of silencing PDK1 expression on
the ability of liver-metastatic cells to grow as primary tumors or
form liver metastases. Parental 2776 or 2792 liver-metastatic
cells, or liver-metastatic cells expressing control shRNA (shLUC)
or shRNA targeting PDK1 (shPDK1), were injected into the mam-
mary fat pad of Balb/c mice and primary tumor growth assessed
over time. We observed no statistically significant differences in
primary mammary tumor growth between mice injected with584 Cell Metabolism 22, 577–589, October 6, 2015 ª2015 Elsevier Inparental, shLUC-expressing, or shPDK1-expressing 2776 (Fig-
ure 6A) or 2792 (Figure 6B) cell populations. To test the impact
of silencing PDK1 on the liver-metastatic phenotype of these
cells, we performed experimental metastasis assays via splenic
injection. Three weeks postinjection, livers from recipient mice
were harvested and the metastatic burden quantified. We
observed an 80% reduction in liver metastatic burden in mice
that received 2776-shPDK1 or 2792-shPDK1 cells compared
to mice that had received parental or shLUC-expressing liver-
metastatic cells (Figures 6C and 6D). Histological examination
of livers from thesemice revealed a reduction in both the number
and size of metastatic lesions originating from 2776-shPDK1 or
2792-shPDK1 cells (Figures 6E and 6F). These data suggest
that PDK1 is required for the formation of efficient liver metasta-
ses in this model.
To better define the stage during breast cancer cell seeding
and colonization of the liver that is dependent on PDK1 function,
we performed a short-term seeding assay using CFSE-labeled
2776-shLUC and 2776-shPDK1 cells and assessed the number
of cells present in the liver post-splenic injection. Two hours
postinjection (day 0), the labeled tumor cells remained within
the liver sinusoids, with few extravasated cells visible in either
cohort (Figure S5A). Similar numbers of extravasated breast
cancer cells were quantified at 26 (day 1) and 50 (day 2) hours
postinjection, revealing that the significant reduction in liver-
metastatic burden observed in cells lacking PDK1 (Figure 6)
was not due to a defect in the extravasation potential of the cells
(Figure S5A). To determine if reduced PDK1 expression affects
general metastatic potential, we assessed metastatic burden in
the lung following tail vein injections of the 2776-shLUC and
2776-shPDK1 cells. Interestingly, reduced PDK1 levels did not
affect the ability of breast cancer cells to form lung metastases
(Figure S5B), even though the ability to form liver metastases
was severely impaired (Figure 6). These data argue that the
importance of PDK1 in the metastatic process becomes evident
following tumor cell adaptation to the liver microenvironment.
PDK1 Expression Is Elevated in Liver Metastases
from Breast Cancer Patients
To further study the role of PDK1 in human metastatic breast
cancer, we investigated its level of expression by immunohisto-
cytochemistry in a breast tumormicroarray containing 330 tumor
cores that were linked to clinical outcomes. Of these cores, 282
could be scored for PDK1 expression. We saw no association
between high levels of PDK1 expression in the primary breast
tumor and breast cancer-specific patient survival (Figures S6A
and S6B). Next, we assessed PDK1 expression by IHC in liver
metastases from nine breast cancer patients as well as seven
matched primary breast tumor sections (Figure 7). Analysis of
these tumor sections revealed considerable variability in PDK1
expression in primary breast tumors, but consistent increases
in PDK1 staining (either signal intensity or percentage positivity
of PDK1 staining) in liver metastases compared to matched
primary tumors in all seven patients examined. Two additional
liver metastases from breast cancer patients, for which insuffi-
cient tumor cells could be identified in the primary tumor, also
revealed higher PDK1 signal compared to the average intensity
found in the other primary tumors. To determine if PDK1 expres-
sion was elevated in all metastases, regardless of site, wec.
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Figure 6. PDK1 Expression Is Critical for Efficient Breast Cancer Liver Metastasis
(A and B) Tumor growth following mammary fat pad injections of parental, control and PDK1 KD cells in either 2776 (A) or 2792 (B) breast cancer populations.
(C and D) Liver-metastatic burden was calculated following splenic injections of the 2776 (C) or 2792 (D) populations (n = 6 for 2776, n = 8 for 2776-shLUC, n = 10
for 2776-shPDK1, n = 9 for 2792, n = 6 for 2792-shLUC and n = 10 for 2792-shPDK1). (C) ***p < 0.001 (SEM); (D) ***p < 0.001 (SEM).
(E and F) Representative images of liver sections stained with H&E. (***p < 0.001).analyzed the PDK1 expression in five matched primary breast
tumors and skin metastases. Interestingly, we did not observe
an increase in PDK1 staining in skin metastases compared to
their matched primary tumors (Figure S6C). Together these
data suggest an important role for PDK1 in mediating liver
metastasis in human breast cancer.
DISCUSSION
Renewed attention has been focused on alteredmetabolism that
accompanies tumor initiation and growth in the primary site
(Ward and Thompson, 2012). However, there have been conflict-
ing opinions regarding the metabolic programs that underpin the
metastatic process in breast cancer. Previous efforts to define
the metabolic profiles of metastatic breast cancer cells revealed
a progressive shift toward a glycolytic phenotype as normal
mammary epithelial cells progress to non-metastatic breast
cancer, with further changes in both glycolytic and OXPHOS
metabolite levels in metastatic breast cancer (Lu et al., 2010).
The authors concluded that no further metabolic changes corre-
lated with the acquisition of increasing metastatic activity (Lu
et al., 2010). Others have identified OXPHOS and increased
mitochondrial activity as important contributors to themetastatic
phenotype (LeBleu et al., 2014; Porporato et al., 2014). Here we
demonstrate that breast cancer cells transitioning to the meta-Cellstatic state display increases in both OXPHOS and glycolysis,
but that additional, distinct metabolic changes are associated
with site-specific metastases. Our data suggest that breast can-
cer cells with broad metastatic potential (4T1—bone, lung, and
liver) engage both OXPHOS and glycolysis, while cells with
site-selective metastatic potential engage OXPHOS (bone or
lung-metastatic cells) or glycolysis-dependent (liver-metastatic
cells) metabolic strategies. We demonstrate that liver-specific
metastatic breast cancer cells are specifically programmed—
via HIF-1a, and PDK1—to maintain their glycolytic phenotype,
and that PDK1 is required for these breast cancer cells to suc-
cessfully metastasize to the liver. The emergence of elevated
PDK1 levels in liver metastases from breast cancer patients,
even in patients with low PDK1 expression in their primary tu-
mors, suggests that active shifts in metabolic reprogramming
may contribute to metastatic progression in human disease.
In our model, metastatic breast cancer populations (66cl4,
4T1 cells) displayed elevated OXPHOS and TCA cycle activity
compared to non-metastatic cell variants (67NR), with highly
metastatic 4T1 cells also displaying significant increases in
glycolytic metabolism. Other groups have found a similar shift to-
ward mitochondrial metabolism in metastatic cells (LeBleu et al.,
2014; Porporato et al., 2014). For example, PGC-1a-dependent
increases in mitochondrial biogenesis, respiration, and oxidative
capacity are required for 4T1 cells to effectively form lungMetabolism 22, 577–589, October 6, 2015 ª2015 Elsevier Inc. 585
Figure 7. PDK1 Expression Is Elevated in Liver Metastases Derived from Patients with Breast Cancer Relative to Matched Primary Breast
Tumors
Representative images of PDK1 staining in primary human breast tumors andmatched liver metastases are shown. The scale bar represents 50 mmand applies to
all panels. Graphs corresponding to the quantification of PDK1 staining and representing the percentage positivity as well as the staining intensity (0 = negative,
1 = weak, 2 = moderate, and 3 = strong) in both the primary tumors (white bars) and liver metastases (black bars) are presented.metastases (LeBleu et al., 2014). However, our work also sug-
gests that breast cancer cells with similar genetic backgrounds,
but with preferential metastatic tropism to different sites, display
distinct metabolic profiles. Our data suggest that a bifurcation of
metabolic programs between OXPHOS (favored by lung and
bone metastases) and glycolytic metabolism (liver metastases)
may define metastatic fitness to specific sites, leading to the
discrepancy between these studies. These data are in agree-
ment with recent work demonstrating that the metabolic profile
of tumor cells depends not only on the driving oncogenes but
also on the tissue type (Yuneva et al., 2012).
Our data highlight a key role for HIF-1a and PDK1 in the glyco-
lytic program engaged by liver-metastatic breast tumor cells.
Interestingly, while HIF-1a appeared to be a master regulator
of the metabolic phenotype under basal conditions, PDK1 was
specifically required for metabolic adaptation in response to
metabolic stress. The reduction of both lung and liver metastasis586 Cell Metabolism 22, 577–589, October 6, 2015 ª2015 Elsevier Inin breast cancer cells harboring reduced HIF-1a levels also
supports a broader functional role for this transcription factor
in themetastatic process. In contrast, reduced PDK1 expression
appears to play amore restricted role in controlling themetabolic
fitness of cancer cells under metabolic stress associated with
certain microenvironments.
Contradictory data exist with respect to the role of the PDKs in
regulating tumor metabolism and growth. PDK1 was originally
characterized as a key inhibitor of pyruvate entry into the TCA
cycle under hypoxic growth conditions (Kim et al., 2006; Papan-
dreou et al., 2006). Our data indicate that silencing PDK1 in liver-
metastatic breast cancer cells has no effect on basal tumor
metabolism and primary tumor growth. Rather, we find that,
under conditions of limited oxygen or glucose, reducing PDK1
expression in metastatic breast cancer cells dramatically affects
their ability to use glucose asmitochondrial fuel sources. Several
studies argue that PDK1 inhibition is sufficient to revert thec.
glycolytic phenotype leading to increased mitochondrial respira-
tion and altered tumor growth (Bonnet et al., 2007; Sutendra
et al., 2013). However, it is important to note that many of these
studies employed dichloroacetate (DCA) as a PDK inhibitor. In
addition to inhibiting PDK-dependent PDH phosphorylation,
DCA can also reduce HIF-1a levels (Kumar et al., 2012; Sutendra
et al., 2013) and induce oxidative stress responses (Hassoun and
Ray, 2003). Thus, the antitumor effects of DCA treatment may
not be solely due to its effects on PDK activity. Our results argue
that PDK1 is required to mediate the adaptability of liver-meta-
static breast cancer cells to better deal with stresses encoun-
tered during metastatic dissemination, such as the adaptation
to a new microenvironment. In agreement with this, we show
that PDK1 expression is enhanced in liver metastasis of breast
cancer patients compared to their matched primary tumor. Inter-
estingly, a similar increase is not observed in skin metastases
relative to matched primary breast tumors.
One question that arises from our work is, why is themetabolic
program of liver-specific metastatic cells different than those
that colonize different sites? Indeed, bone- and lung-specific
metastases directed pyruvate into the TCA cycle to support
OXPHOS and mitochondrial-dependent biosynthesis, while
liver-metastatic breast cancer cells preferentially converted py-
ruvate into lactate, characteristic of theWarburg effect. Similarly,
liver-aggressive cells displayed reduced levels of glutamine
oxidation, and increasingly generated glutamine-derived citrate
for biosynthesis via reductive carboxylation. Thus, while the
bioenergetic and biosynthetic requirements of all metastatic
populations are met, the liver-metastatic cells achieved this
through different metabolic programs. In this context, liver-met-
astatic breast cancer cells have adopted a metabolic profile
similar to that of cells grown under hypoxia. In addition to
increased glycolysis and reduced TCA cycle activity, hypoxia
or pseudohypoxia was shown to reduce glutamine oxidation
and favor reductive carboxylation to produce citrate through
HIF-dependant induction of Isocitrate dehydrogenase (IDH)
and bypass of the mitochondrial-dependent production of
acetyl-CoA from glutamine for de novo lipogenesis (Metallo
et al., 2012; Wise et al., 2011). Alternatively, it has been shown
that HIF-1 stabilization diminishes the conversion aKG to succi-
nate through loss of OGDH2, a subunit of the aKG dehydroge-
nase (aKGDH) complex (Sun and Denko, 2014). Under these
conditions, glutamine undergoes reductive carboxylation to
produce citrate for lipid synthesis (Sun and Denko, 2014). Our
data suggest that the HIF-1a-dependent metabolic signature
displayed by the liver-metastatic breast cancer cells is already
present in subsets of cells that comprise the parental 4T1 popu-
lation. Altogether, this suggests a potential selection formetasta-
tic cells that have gained additional mutations or epigenetic
changes that favor themetabolic programs required for success-
ful metastasis to specific sites. In addition, our short-termmetas-
tasis assay suggests that the impaired metastatic potential of
tumor cells lacking PDK1 results from growth defects within the
liver rather than a deficiency in the initial seeding of the organ.
By virtue of its function as a gluconeogenic tissue, the liver
may provide a conducive microenvironment for metastatic
breast cancer cells whose growth is fueled by glycolysis. Our
data show that metastatic breast cancer cells isolated from
the liver exhibit high levels of glycolytic metabolism and lactateCellproduction. Hepatocytes may take up lactate (or other tumor-
derived metabolites) and convert them into other metabolites
that can then feed back to cancer cells to fuel their growth. Meta-
bolic coupling of cancer cells and non-transformed stromal cells
is observed in ovarian cancer, where adipocytes can transfer
lipids to adjacent tumor cells to fuel OXPHOS (Nieman et al.,
2011). In this light, we speculate that liver-metastatic breast can-
cer cells are metabolically coupled to hepatocytes on the basis
of glucose availability, and that HIF-1a and PDK1 help confer
compatibility of these tumor cells with the liver. Understanding
the metabolic codependencies of metastatic breast cancer cells
with their local microenvironments may reveal potential vulnera-
bilities suitable for therapeutic targeting.
EXPERIMENTAL PROCEDURES
Cell Lines, Cell Culture, and DNA Constructs
67NR, 66cl4, and 4T1 cell lines were cultured as previously described (Rose
et al., 2007). The 4T1-derived liver-aggressive (2776 and 2792), lung-aggres-
sive (533 and 537), and bone-aggressive cell populations (592 and 593)
were described previously (Tabarie`s et al., 2015). Proliferation rates were
determined by seeding cells in 6-well plates and performing cell counts every
day over a 4-day period to determine population doublings. ROS levels were
measured using MitoSOX Red mitochondrial superoxide indicator (Invitrogen,
#M36008) following a 15min incubation period, andMean Fluorescence Inten-
sity (MFI) determined by flow cytometry. HIF-1a knockdown was achieved
using lentiviral shRNA vectors from the TRC shRNA collection (Sigma-Aldrich,
St. Louis, MO; TRCN0000232220 [hp#1] and TRCN0000232222 [hp#2]). Len-
tiviral supernatants were generated as described (Huang et al., 2012). PDK1
knockdown was achieved using the miR-30-adapted LMP retroviral vector
system (Dickins et al., 2005).
Metabolic Assays
Glucose consumption and lactate production were measured using a Nova
BioProfile 400 (Nova Biomedical, Mississauga, ON, Canada) using established
protocols (Dupuy et al., 2013; Faubert et al., 2014). ECAR and OCR were
measured using an XF24 or XF96 Extracellular Flux Analyzer (Seahorse Biosci-
ence, North Billerica, MA, USA) as previously described (Dupuy et al., 2013).
Respiration measurements were performed using a Digital Model 10 Clarke
Electrode (Rank Brothers, Cambridge, UK). Total respiration was determined
for 1 3 106 cells, and maximal respiratory capacity was determined after the
addition of FCCP (1.5 mM).
GC-MS Analysis of 13C Metabolites
GC-MS and SITA experiments were conducted as previously described (Du-
puy et al., 2013; Faubert et al., 2014). Cells (1–2 3 106 cells/6 cm dish) were
grown for 24 hr, followed by incubation for 15–30 min in glucose or gluta-
mine-freemediumcontaining 10%dialyzedFBS (Wisent) anduniformly labeled
U-[13C]-glucose or U-[13C]-glutamine (Cambridge Isotope Laboratories) (Fau-
bert et al., 2013). All labeling experiments were performed in duplicate and
repeated three times; thegraphs correspond toone representative experiment.
Microarray Analysis
RNA was extracted from 4T1 parental and individual in vivo selected metasta-
tic subpopulations; purified total RNA was subjected to amplification and
hybridized to 44K whole-mouse genome microarray gene expression chips
(Agilent Technologies, Mississauga, ON, Canada) as described previously
(Tabarie`s et al., 2015). The microarray data can be accessed through the
GEO repository (ID GSE62598).
HIF Reporter Assay
Breast cancer cells were cotransfected with a HIF luciferase reporter (pGL2-
TK-HRE, 0.5 mg) (Rapisarda et al., 2002) and a Renilla luciferase expression
vector (0.25 mg). Luciferase activity in transfected cells was determined
48 hr later by Dual-Glo Luciferase Assay (Promega, Madison, WI, USA) and
normalized to Renilla luciferase activity. HIF-dependent luciferase activityMetabolism 22, 577–589, October 6, 2015 ª2015 Elsevier Inc. 587
was measured under basal conditions, or following 24 hr incubation in 1%
oxygen. The data are expressed as the fold change in HIF reporter activity
relative to 4T1 cells and correspond to an average of three experiments per-
formed in duplicate.
Immunoblotting and qPCR
Immunoblots were performed as previously described (Tabarie`s et al., 2011).
RNA extraction, cDNA synthesis, and qPCR were performed as previously
described (Dupuy et al., 2013). Real-time qPCR was performed using an
Applied Biosystems 7500 instrument (Applied Biosystems) using the primers
listed in Table S4. Transcript expression was determined relative to Rpl13
mRNA levels and expressed as the fold change compared to control 4T1 cells.
The data represent the average of three independent experiments from three
biological replicates per experiment.
In Vivo Tumor Growth and Metastatic Seeding Assays
13 104 cells were injected into themammary fat pads of Balb/cmice to assess
primary tumor cell growth as previously described (Tabarie`s et al., 2011). For
experimental metastasis assays, 13 105 cells were injected into the spleens or
the tail vein of female Balb/c mice as previously described (Tabarie`s et al.,
2011) to assess metastatic potential to the liver and lung, respectively. For
short-term in vivo seeding assay, CFSE-labeled (Invitrogen) cells (1 3 105)
were subjected to splenic injection as previously described (Tabarie`s et al.,
2012). After 2, 26, and 50 hr postinjection, seven to ten mice per cohort
were sacrificed, and livers were collected and whole-mounted for imaging.
The number of extravasated CFSE-labeled breast cancer cells per field was
assessed using an inverted microscope (Zeiss Axiozoom.V16), and seven
fields were quantified per animal. The mice were housed in facilities managed
by the McGill University Animal Resources Centre, and all animal experiments
were conducted under a McGill University-approved Animal Use Protocol in
accordance with guidelines established by the Canadian Council on Animal
Care.
Human Clinical Samples, Immunohistochemistry, and Scoring
Tissue microarrays (TMAs) were designed and constructed as described
previously (Hsu et al., 2002; Makretsov et al., 2003). Immunohistochemical
staining for PDK-1 was performed on paraffin-embedded sections using an
anti-PDHK-1 antibody (1:50 dilution, C47H1 #3820, Cell Signaling Technology,
Danvers, MA).
Statistical Analyses
Data are presented as mean ± SD for technical replicates, or mean ± SEM
for biological replicates, and analyzed using unpaired Student’s t test
(VassarStats software). Statistical significance is indicated in all figures by
the following annotations: *p < 0.05; **p < 0.01; ***p < 0.001.
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